MAM
KDNY

Meeder Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Meeder Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,299
Closed -$26K – 2442
2020
Q2 		$26K Sell
2,299
-69
-3% -$951 ﹤0.01% 1080
2020
Q1 		$32K Buy
+2,368
New +$28K ﹤0.01% 1072
2019
Q4 		– Sell
-1,131
Closed -$7K – 2464
2019
Q3 		$7K Buy
1,131
+889
+367% +$5.9K ﹤0.01% 1671
2019
Q2 		$2K Buy
242
+44
+22% +$670 ﹤0.01% 1897
2019
Q1 		$4K Sell
198
-27
-12% -$471 ﹤0.01% 1461
2018
Q4 		$3K Buy
225
+54
+32% +$1.08K ﹤0.01% 1537
2018
Q3 		$6K Buy
+171
New +$5.49K ﹤0.01% 1305
2018
Q1 		– Sell
-26
Closed -$1K – 1793
2017
Q4 		$1K Sell
26
-21
-45% -$917 ﹤0.01% 1612
2017
Q3 		$3K Sell
47
-161
-77% -$9.57K ﹤0.01% 1401
2017
Q2 		$12K Sell
208
-368
-64% -$18.5K ﹤0.01% 963
2017
Q1 		$31K Buy
576
+368
+177% +$20.8K ﹤0.01% 669
2016
Q4 		$12K Buy
+208
New +$12.6K ﹤0.01% 730

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Meeder Asset Management's KDNY Position: Q3 2020 in Review

Meeder Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2020, closing a stake of 2,299 shares — an estimated $26K sold.

Meeder Asset Management first reported a position in KDNY in Q4 2016 and held it in 12 quarters. The position peaked at $32K in Q1 2020. 70 funds tracked by Wall St. Rank hold KDNY as of Q3 2020.

  • Meeder Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Meeder Asset Management sold 2,299 Chinook Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $26K.
  • Meeder Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2016 and held it in 12 quarters.
  • Meeder Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $32K in Q1 2020.
  • 70 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Meeder Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.